In 2020, results from the IMBrave150 study significantly changed the landscape of systemic therapy in HCC, and the combination of atezolizumab, an ICI that targets anti–programmed cell death ligand-1 (PD-L1), and bevacizumab, an anti-angiogenic mAb targeting vascular endothelial growth factor A (VEGF-A), has now been established as the first-line treatment for unresectable HCC worldwide (12). The gene discussed is VEGFA; the disease is hepatocellular carcinoma.